Intermolecularが2018年第2四半期決算を発表（前半）

AsiaNet 74682 （1371）

【サンノゼ（カリフォルニア州）2018年8月7日PR Newswire＝共同通信JBN】

＊プログラム売上高が前年同期比45%増え、50万ドルの純利益と19%の調整済みEBITDA（利払い前・税引き前・減価償却前利益）マージンを達成

先端材料イノベーションの信頼されるパートナーであるIntermolecular, Inc.（NASDAQ: IMI）は7日、2018年6月30日に終了した第2四半期の決算を発表した。

▽2018年第2四半期の財務・運営業績ハイライト

＊総売上高は980万ドルで前期比1%増、前年同期比45%増

＊プログラム売上高は前期比1%増、前年同期比45%増

＊純利益は50万ドル。前年同期は290万ドルの純損失

＊総現金・投資は前期比400万ドル増の3130万ドルないし希薄化後1株当たり0.63ドル

＊同四半期中に新たに2件の契約を確保

▽経営陣のコメント

Intermolecularのクリス・クレイマー社長兼最高経営責任者（CEO）は「Intermolecularは2018年第2四半期に50万ドルの純利益と4期連続でポジティブな調整済みEBITDAを達成した。売上高、粗利益、純利益の占める比率はIPO（新規株式公開）以来最高である。これらの成果は、われわれが顧客エンゲージメントを拡大し、コスト構造を削減し、利益が出るようにサービス事業を構築するためにこの1年間に取った戦略的行動の結果である。2018年上半期の業績をみると、プログラム売上高は40%超増え、280万ドルの調整済みEBITDAを生んだ」と語った。

▽2018年第2四半期決算

2018年第2四半期の売上高は980万ドルで、2018年第1四半期の970万ドルに比べ1%増、前年同期の810万ドルに比べ21%増だった。プログラム売上高は前期比1%増、前年同期比45%増の940万ドルだった。

2018年第2四半期の総営業経費は670万ドルで、2018年第1四半期の710万ドルに比べ6%減、前年同期の850万ドルに比べ22%減だった。

2018年第2四半期の純利益は50万ドル、基本的および希薄化後1株当たり0.01ドルの利益だった。前期の60万ドルの純損失、基本的および希薄化後1株当たり0.01ドルの損失と、前年同期の290万ドルの純損失、基本的および希薄化後1株当たり0.06ドルの損失から改善した。

2018年第2四半期のNon-GAAP純利益は70万ドル、基本的および希薄化後1株当たり0.01ドルの利益だった。前期は40万ドルのnon-GAAP純損失、基本的および希薄化後1株当たり0.01ドルの損失、前年同期は250万ドルのnon-GAAP純損失、基本的および希薄化後1株当たり0.05ドルの損失だった。

2018年第2四半期の調整済みEBITDAは180万ドルと、前期の100万ドルの調整済みEBITDA、前年同期の100万ドルの調整済みEBITDA損失から改善した。

2018年第2四半期末の現金・投資は3130万ドルと、2018年第1四半期末の2720万ドルから400万ドル増加した。四半期末の債務はなかった。

▽2018年財務見通し

クレイマー氏は「当社の第3四半期の業績は、特定のプログラムの成功裏の終了と、当社で進行中の他のプログラム機会の実行における一時的な遅延によって影響を受けると予想している。主要顧客との関係は素晴らしく、既存のプログラムの完成は将来のビジネスに役立つ成功したコラボレーションの結果であることを強調したい。これらの機会の多くは第4四半期に実現し、同四半期業績は第3四半期と比較して大幅に改善するとみている。これらの一時的な遅れを考慮し、サービス事業の年央の成長率は前年同期比15%増となることから、2018年度の収益予想を3400万ドルから3600万ドルの間と更新した。当社は2019年を見据えて、利益が出るように事業を成長・拡大させ続ける能力に引き続き自信を持っている」と述べた。

以下の記述は、2018年9月30日に終了する第3四半期に関するIntermolecularの現在の見通しに基づく。以下の見通しは将来の見通しに関するものであり、実際の業績は、市場条件および下記の「将来の見通しに関する記述」に記載されている要因によって大きく異なる可能性がある。Intermolecularは今後、この見通しの更新を予定しておらず、将来この見通しを更新するいかなる義務も負わない。

＊売上高は650万－750万ドルと見込まれる。

＊170万－280万ドルの純損失、発行済み株式数が約4970万株との前提に基づき、1株当たり0.04－0.06ドルの損失が予測される。

＊株式報酬費用を除くNon-GAAP純利益は、140万－250万ドルの損失、発行済み株式数が4970万株との前提に基づき、1株当たり0.03－0.05ドルの損失と予測される。

＊調整済みEBITDA損失は60万－170万ドルと予測される。

Intermolecularは米国一般会計基準（GAAP）に従い、そして追加的に非GAAPベースで、売上高、売上原価、粗利益、営業利益（損失）、純利益（純損失）および1株当たり利益（損失）を報告している。非GAAP財務指標と最も直接的に比較可能なGAAP指標との調整、並びに非GAAP指標から除外された項目の記述は、本プレスリリースの財務諸表に含まれている。以下の「GAAPと非GAAP財務指標の調整」および「GAAP純利益／損失から非GAAP純利益への調整」を参照。

▽カンファレンスコール

Intermolecularは米東部時間2018年8月6日午後5時（米太平洋時間午後2時）からカンファレンスコールおよび同時ウェブキャスト（音声のみ）を開催し、これらの業績について議論する。カンファレンスコールはIntermolecularのクリス・クレイマー社長兼CEOおよびビル・ロシュレイン最高財務責任者（CFO）が主催する。

直通電話番号

米国：+1 (877) 251-1860

海外から：+1 (224) 357-2386

Conference ID：1997328

開始時間の5－10分前に上記の番号に電話を。オペレーターがあなたの名前と組織を登録する。カンファレンスコールとの接続が困難な場合には、+1 (949) 574-3860に電話し、Liolios Groupと接触を。

カンファレンスコールの生放送およびウェブキャスト（音声のみ）は、終了後最長30日間、Intermolecularのウェブサイト（http://ir.intermolecular.com/ ）で利用可能。

▽Intermolecular, Inc.について

Intermolecular（R）は先端素材イノベーションの信頼されるパートナーである。先端素材は、半導体、家電、自動車、航空宇宙を含む幅広い産業のための21世紀におけるイノベーションの中核である。Intermolecularは豊富な素材に関する専門知識、加速学習・実験プラットフォーム、そして情報・分析インフラストラクチャーで、10年間にわたり大手企業が素材イノベーションを加速し、リスクを極小化するのをサポートしてきた。詳細は、www.intermolecular.com を参照。

「Intermolecular」およびIntermolecularロゴは登録商標である。不許複製。

▽非GAAP財務指標

当社はGAAPベースで提示された財務データを補足するため、株式報酬費用の影響を除いた特定の非GAAP財務指標も開示している。これらの非GAAP財務指標は、GAAPに準拠して作成されたものではなく、GAAPに代わるものでもない。他の企業が開示した非GAAP財務情報とは異なる方法で算出される可能性もある。これらの結果は、当社の業績をそれと対応するGAAP指標と併せて評価するためにのみ使用される必要がある。われわれは、非GAAP財務指標は経営陣がIntermolecularの中核事業の業績の外にあると判断した費用を除外しているため、非GAAP財務情報は経営陣および投資家に対し、当社の財務状態および経営成績に関連する財務および事業の傾向に関する有益な情報を提供すると考えている。当社は、GAAPに従って計算された当社の財務実績と対応して見られる非GAAPベースの売上高、売上原価、粗利益、売上総利益、営業利益（損失）、純利益（純損失）および1株当たり利益（損失）という非GAAP財務指標は、投資家にさらなる視点と継続的な業績のより意味のある理解を提供すると考える。さらに、経営幹部は、これらの非GAAP指標を使用して、財務実績をレビューおよび評価し、幹部職員のインセンティブ報酬を決定し、将来の業績を計画および予測する。

▽企業問い合わせ先

Bill Roeschlein

Intermolecular, Inc.

Chief Financial Officer

bill.roeschlein@intermolecular.com

+1 (408) 582-5415

▽投資家問い合わせ先

Matt Glover or NajimMostamand, CFA

Liolios Group, Inc.

IMI@liolios.com

+1 (949) 574-3860

Logo - https://mma.prnewswire.com/media/327096/Intermolecular_Logo.jpg

ソース：Intermolecular, Inc.

Intermolecular Reports Second Quarter 2018 Financial Results（Part 1）

PR74682

SAN JOSE, Calif., Aug. 7, 2018 /PRNewswire=KYODO JBN/ --

-- Program Revenue Up 45% Year-over-Year, Driving Net Income of $0.5 million

and 19% Adjusted EBITDA Margin

Intermolecular, Inc. (NASDAQ: IMI), the trusted partner for advanced materials

innovation, today reported results for its second quarter ended June 30, 2018.

Q2 2018 Financial and Operational Highlights

    - Revenue was $9.8 million, an increase of 1% sequentially and 21% over

      the prior year.

    - Program revenue grew 1% sequentially and 45% over the prior year.

    - Net income totaled $0.5 million compared with a net loss of $(2.9)

      million in the prior year.

    - Total cash and investments increased $4 million from the prior quarter

      to $31.3 million or $0.63 per diluted share.

    - Secured two new contracts during the quarter.

Management Commentary

"Intermolecular achieved net income of $0.5 million in the second quarter of

2018 along with our fourth consecutive period of positive adjusted EBITDA,"

said company president and CEO, Chris Kramer. "As a percentage of revenue, our

gross margins and net income were the highest since our IPO. These achievements

are the result of the strategic actions we have taken over the past year to

increase customer engagements, reduce our cost structure, and profitably build

our services business. Looking at our performance for the first half of the

year, our program revenue grew by more than 40% and we generated $2.8 million

in adjusted EBITDA."

Second Quarter of 2018 Financial Results

Revenue for the second quarter of 2018 was $9.8 million, up 1% compared to $9.7

million in the first quarter of 2018, and up 21% compared to $8.1 million in

the same period a year ago. Program revenue grew 1% sequentially and 45% over

the same period a year ago to $9.4 million.

Total operating expenses for the second quarter of 2018 were $6.7 million, down

6% compared to $7.1 million in the first quarter of 2018, and down 22% compared

to $8.5 million in the same period a year ago.

Net income for the second quarter of 2018 totaled $0.5 million, or $0.01 per

basic and diluted share, an improvement from net loss of $(0.6) million, or

$(0.01) per basic and diluted share in the prior quarter, and net loss of

$(2.9) million, or $(0.06) per basic and diluted share in the same period a

year ago.

Non-GAAP net income for the second quarter of 2018 totaled $0.7 million, or

$0.01 per basic and diluted share, compared to non-GAAP net loss of $(0.4)

million, or $(0.01) per basic and diluted share in the prior quarter, and

non-GAAP net loss of $(2.5) million, or $(0.05) per basic and diluted share in

the same period a year ago.  

Adjusted EBITDA for the second quarter of 2018 totaled $1.8 million, an

improvement from $1.0 million in the prior quarter and an adjusted EBITDA loss

of $(1.0) million in the same period a year ago.  

Cash and investments totaled $31.3 million at the end of second quarter of

2018, an increase of $4.0 million compared to $27.2 million at the end of first

quarter of 2018. The company had no debt at quarter end.    

2018 Financial Outlook

"We anticipate that our third quarter financial results will be impacted by the

successful conclusion of certain programs as well as temporary delays in the

execution of other program opportunities in our pipeline," said Kramer. "We

would like to emphasize that our relationships with our major customers are

excellent and the completion of an existing program was the result of a

successful collaboration that bodes well for future business. We expect many of

these opportunities to materialize in the fourth quarter, giving us confidence

that our financial results for Q4 will be substantially better compared to the

third quarter. Given these temporary delays, we are updating our revenue

guidance for fiscal 2018 to be between $34 million and $36 million, highlighted

by 15% year-over-year growth in our services business at the midpoint. As we

look ahead to 2019, we remain confident in our ability to continue to grow and

scale our business profitably."

The following statements are based on Intermolecular's current expectations for

the third quarter ending September 30, 2018. The following statements are

forward-looking, and actual results could differ materially depending on market

conditions and the factors set forth under "Forward-Looking Statements" below.

Intermolecular does not plan to update, nor does it undertake any obligation to

update, this outlook in the future.

    - Revenue is projected to be in the range of $6.5 million to $7.5 million;

    - Net loss is projected to be between a loss of $(1.7) million and $(2.8)

      million, or $(0.04) per share and $(0.06) per share, based on

      approximately 49.7 million shares expected to be outstanding;

    - Non-GAAP net income, excluding stock-based compensation expense, is

      projected to be between a loss of $(1.4) million and $(2.5) million, or

      $(0.03) per share and $(0.05) per share, based on approximately 49.7

      million shares expected to be outstanding; and,

    - Adjusted EBITDA loss is projected to be between $(0.6) million and

      $(1.7) million.

Intermolecular reports revenue, cost of revenue, gross margin, operating income

(loss), net income (loss) and earnings (loss) per share in accordance with U.S.

generally accepted accounting principles (GAAP) and additionally on a non-GAAP

basis. A reconciliation of the non-GAAP financial measures with the most

directly comparable GAAP measures, as well as a description of the items

excluded from the non-GAAP measures, is included in the financial statements

portion of this press release. Please refer to "Reconciliation of GAAP to

Non-GAAP Financial Measures" and "Reconciliation of GAAP Net Income/Loss to

Non-GAAP Net Income" below.

Conference Call

Intermolecular will host a conference call and simultaneous audio-only webcast

today (August 6, 2018) at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) to

discuss these results. The call will be hosted by Intermolecular President and

CEO Chris Kramer and CFO Bill Roeschlein.

U.S. dial-in number: +1 (877) 251-1860

International dial-in number: +1 (224) 357-2386

Conference ID: 1997328

Please call the conference telephone number five to ten minutes prior to start

time. An operator will register your name and organization. If you have

difficulty connecting with the conference call, please contact Liolios Group at

+1 (949) 574-3860.

A live and archived webcast (audio only) of the call will be available on

Intermolecular's website (http://ir.intermolecular.com/ ) for up to 30 days

after the call.

About Intermolecular, Inc.

Intermolecular(R) is the trusted partner for advanced materials innovation.

Advanced materials are at the core of innovation in the 21st century for a wide

range of industries including semiconductors, consumer electronics, automotive

and aerospace. With its substantial materials expertise; accelerated learning

and experimentation platform; and information and analytics infrastructure,

Intermolecular has a ten-year track record helping leading companies accelerate

and de-risk materials innovation. Learn more at www.intermolecular.com.

"Intermolecular" and the Intermolecular logo are registered trademarks; all

rights reserved.

Forward-Looking Statements

Statements made in this press release and the earnings call referencing the

press release that are not statements of historical fact are forward-looking

statements. Forward-looking statements are subject to the "safe harbor"

provisions of the Private Securities Litigation Reform Act of 1995.

Forward-looking statements are commonly identified by words such as "would,"

"may," "expects," "believes," "plans," "intends," "projects" and other terms

with similar meaning. Investors are cautioned that the forward-looking

statements in this document are based on current beliefs, assumptions and

expectations, speak only as of the date of this document and involve risks and

uncertainties that could cause actual results to differ materially from current

expectations. Such statements are subject to certain known and unknown risks

and uncertainties, many of which are difficult to predict and generally beyond

Intermolecular's control, that could cause actual results and other future

events to differ materially from those expressed in, or implied or projected

by, the forward-looking information and statements. Material factors that could

cause actual results to differ materially from current expectations include,

without limitation, the following: our ability to productize our workflows with

existing and future customers; expectations regarding our future revenue, cash

flow and GAAP and non-GAAP net income or loss; financial condition; the ability

of our new business model to generate profits and long-term shareholder

returns; the extent to which technology developed in collaboration with our

customers will continue to remain on the critical path and have significant

value for such customers and us as well as the industry as a whole; and

anticipated growth in our current markets through expansion of existing

customer programs and the entry into other engagements with new customers.

Forward-looking statements are subject to risks and uncertainties that could

cause actual results to differ materially from expectations, including but not

limited to: our ability to execute on our strategy, prove our business model

and remain technologically competitive in rapidly evolving industry conditions;

commercial acceptance of our HPC platform and methodology as effective R&D

tools; our ability to achieve and sustain profitability; the ability of our

customers to achieve their announced product roadmaps in a timely manner; the

extent to which we are able to successfully extend and expand relationships

with existing customers; our ability to manage the growth of our business; the

rapid technology changes and volatility of the customers and industries we

serve; our potential need for future capital to finance our operations; and

other risks described in our most recent annual report on Form 10-K as updated

by our quarterly reports on Form 10-Q and other filings with the Securities and

Exchange Commission available at www.sec.gov, particularly in the sections

titled "Risk Factors." All forward-looking statements are based on management's

current estimates, projections and assumptions, and we assume no obligation to

update them.

Non-GAAP Financial Measures

To supplement the financial data presented on a GAAP basis, we also disclose

certain non-GAAP financial measures, which exclude the effect of stock-based

compensation expense. These non-GAAP financial measures are not prepared in

accordance with GAAP, do not serve as an alternative to GAAP and may be

calculated differently than non-GAAP financial information disclosed by other

companies. These results should only be used to evaluate our results of

operations in conjunction with the corresponding GAAP measures. We believe that

our non-GAAP financial information provides useful information to management

and investors regarding financial and business trends relating to our financial

condition and results of operations because the non-GAAP measures exclude

charges that management considers to be outside of Intermolecular's core

operating results. We believe that the non-GAAP measures of revenue, cost of

net revenue, gross profit, gross margin, operating (loss) income, net (loss)

income, earnings per share and net (loss) income per share, viewed in

combination with our financial results calculated in accordance with GAAP,

provide investors with additional perspective and a more meaningful

understanding of our ongoing operating performance. In addition, management

uses these non-GAAP measures to review and assess financial performance, to

determine executive officer incentive compensation and to plan and forecast

performance in future periods.

Corporate Contact:

Bill Roeschlein

Intermolecular, Inc.

Chief Financial Officer

bill.roeschlein@intermolecular.com

+1 (408) 582-5415

Investor Contact:

Matt Glover or Najim Mostamand, CFA

Liolios Group, Inc.

IMI@liolios.com

+1 (949) 574-3860

Logo - https://mma.prnewswire.com/media/327096/Intermolecular_Logo.jpg

SOURCE: Intermolecular, Inc.